Table 6.
Groups |
Serum lipid profile |
||||
---|---|---|---|---|---|
Total cholesterol (TC) (mg/dL) | HDL cholesterol (HDL-c) (mg/dL) | LDL cholesterol (LDL-c) | Triglycerides (TG) (mg/dL) | Hepatic glycogen (mg glucose equivalents/mg wet tissue) | |
Normal rats (untreated with dimethylsulfoxide, [DMSO]) Group 1 |
128.9 ± 0.3926 |
53.19 ± 0.4878 |
27.18 ± 0.5619 |
77.57 ± 0.5943 |
49.7 ± 0.2316 |
Diabetic control (administered with Streptozotocin (STZ) Group 2 |
273 ± 0.7544 |
14.25 ± 0.2791 |
105.81 ± 0.8731ns |
193.1 ± 1.424 |
17.21 ± 0.09793 |
Diabetic control + (ALEx) (100 mg/kg body weight) Group 3 |
201.8 ± 0.3189ns |
15.26 ± 0.1843 |
82.56 ± 0.4372** |
191.7 ± 0.4291 |
19.17 ± 0.1649 |
Diabetic control + (ALEx) (200 mg/kg body weight) Group 4 |
188.1 ± 0.4720 |
28.27 ± 0.5883 |
81.11 ± 1.201 |
161.6 ± 0.5797ns |
25.41 ± 0.4521 |
Diabetic control + (ALEx) (300 mg/kg body weight) Group 5 |
162.8 ± 0.3100** |
34.69 ± 0.5712* |
43.94 ± 0.6629 |
131.3 ± 0.4677 |
38.41 ± 0.2578* |
Diabetic control + (ALEx) (400 mg/kg body weight) Group 6 |
141.4 ± 0.4808*** |
43.74 ± 0.3495*** |
30.09 ± 0.3958*** |
93.57 ± 1.389** |
41.68 ± 0.3041*** |
Diabetic control + Glibenclamide (1 mg/kg b wt.) Group 7 | 145.7 ± 0.5246 | 48.02 ± 0.1643 | 28.51 ± 0.7293 | 81.99 ± 0.5388 | 48.05 ± 0.1163 |
The data are expressed as mean ± SEM. (n = number of animals in each group = 5). The comparisons were made by one way ANOVA followed by Dunnent’s test.
ns = non-significant, STZ = Streptozotocin.
*p < 0.05 is considered as significant when compared to the control group (0 h).
**p < 0.001 is considered as very significant when compared to the control group (0 h).
***p < 0.001 is considered as extremely significant when compared to the control group (0 h).